[go: up one dir, main page]

SV2016005210A - Agonistas de a1 de adenosina como medicamentos para trastornos renales - Google Patents

Agonistas de a1 de adenosina como medicamentos para trastornos renales

Info

Publication number
SV2016005210A
SV2016005210A SV2016005210A SV2016005210A SV2016005210A SV 2016005210 A SV2016005210 A SV 2016005210A SV 2016005210 A SV2016005210 A SV 2016005210A SV 2016005210 A SV2016005210 A SV 2016005210A SV 2016005210 A SV2016005210 A SV 2016005210A
Authority
SV
El Salvador
Prior art keywords
agonists
adenosine
medicines
renal disorders
treat
Prior art date
Application number
SV2016005210A
Other languages
English (en)
Inventor
Barbara Albrecht-Küpper
Kirsten Leineweber
Axel Kretschemer
Daniel Meibom
Alexandros Vakalopoulos
Nicole Diedrichs
Katja Zimmermann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2016005210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2016005210A publication Critical patent/SV2016005210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE SOLICITUD SE RELACIONA CON AGONISTAS DEL RECEPTOR A1 DE ADENOSINA PARCIALES SELECTIVOS DE LA FÓRMULA (I) Y SU USO PARA TRATAR Y/O PREVENIR ENFERMEDADES Y CON SU USO PARA PREPARAR MEDICAMENTOS PARA TRATAR Y/O PREVENIR ENFERMEDADES, PREFERIBLEMENTE PARA TRATAR Y/O PREVENIR TRASTORNOS RENALES AGUDOS Y/O CRÓNICOS (TRASTORNO PRIMARIO Y TRASTORNO SECUNDARIO) CON Y SIN TRASTORNOS CARDIACOS AGUDOS Y/O CRÓNICOS CONCOMITANTES
SV2016005210A 2013-12-12 2016-06-07 Agonistas de a1 de adenosina como medicamentos para trastornos renales SV2016005210A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13196780 2013-12-12

Publications (1)

Publication Number Publication Date
SV2016005210A true SV2016005210A (es) 2017-08-08

Family

ID=49759125

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005210A SV2016005210A (es) 2013-12-12 2016-06-07 Agonistas de a1 de adenosina como medicamentos para trastornos renales

Country Status (21)

Country Link
US (1) US20160311812A1 (es)
EP (1) EP3079696A1 (es)
JP (1) JP2016539986A (es)
KR (1) KR20160094974A (es)
CN (1) CN105792826A (es)
AP (1) AP2016009245A0 (es)
AU (1) AU2014363705A1 (es)
CA (1) CA2933244A1 (es)
CL (1) CL2016001357A1 (es)
EA (1) EA201691218A1 (es)
IL (1) IL245866A0 (es)
MA (1) MA39101A1 (es)
MX (1) MX2016007343A (es)
MY (1) MY174230A (es)
PH (1) PH12016501127A1 (es)
SG (1) SG11201604414PA (es)
SV (1) SV2016005210A (es)
TN (1) TN2016000233A1 (es)
UA (1) UA117771C2 (es)
WO (1) WO2015086561A1 (es)
ZA (1) ZA201603465B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7055429B2 (ja) * 2017-10-27 2022-04-18 学校法人北里研究所 慢性腎臓病の予防又は治療剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102007036075A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Also Published As

Publication number Publication date
PH12016501127A1 (en) 2016-07-18
TN2016000233A1 (en) 2017-10-06
IL245866A0 (en) 2016-07-31
CA2933244A1 (en) 2015-06-18
CL2016001357A1 (es) 2017-01-13
MX2016007343A (es) 2016-09-13
MY174230A (en) 2020-04-01
ZA201603465B (en) 2019-07-31
CN105792826A (zh) 2016-07-20
MA39101A1 (fr) 2017-08-31
KR20160094974A (ko) 2016-08-10
AP2016009245A0 (en) 2016-05-31
AU2014363705A1 (en) 2016-06-30
JP2016539986A (ja) 2016-12-22
UA117771C2 (uk) 2018-09-25
SG11201604414PA (en) 2016-07-28
WO2015086561A1 (de) 2015-06-18
EP3079696A1 (de) 2016-10-19
US20160311812A1 (en) 2016-10-27
EA201691218A1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
ECSP17005276A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MX2016004340A (es) Compuestos heterociclicos y usos de los mismos.
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
UY35500A (es) Indazoles sustituidos con heteroarilo
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
UY35399A (es) Conjugados de fármacos con anticuerpos
UY35350A (es) Pirimidinas condensadas sustituidas con trifluorometilo y su uso
BR112016011195A2 (pt) Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
CL2014001853A1 (es) Compuestos derivados de pirrol sustituido; procedimiento de preparacion; composicion farmaceutica que los contiene; combinacion farmaceutica; uso para tratar enfermedades tales como canceres y enfermedades del sistema inmunitario.
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
BR112016002459A8 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
GT201600132A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
MX387228B (es) Compuestos de pirazol como moduladores del receptor de hormona estimuladora de foliculo y sus usos.
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
GT201400153A (es) Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina
CL2016000325A1 (es) Antagonistas de vía para tratar trastornos del sueño por cambio de fase